Search results for " Oligonucleotide manufacturing"
Article
The oligonucleotide synthesis process consists of a repetitive four-step cycle
The oligo therapeutics market is growing in promise for treating cancers, genetic diseases, and other conditions. In this animated video you can watch the oligonucleotide synthesis process as …
Article
Key Process Considerations for Therapeutic Oligonucleotides
Click here to read the article >>
Learn more about scalable solutions for developing and manufacturing oligonucleotide therapeutics.
Article
Developing oligonucleotide therapeutics with confidence
In this video, we will look at key considerations for oligo therapeutic developers entering the market, such as scalability, flexibility, regulatory concerns, insource/outsource consideratio…
Article
Q&As with Industry Leaders
Discovering the unknown: How does in silico process development change PD scientists’ work?
Jeanne Linke Northrop, BioPharm International
Nora Ketterer, Manager, Modeling Services…
Article
Are you ready to optimize your oligo synthesis?
In this white paper, we share what we learned in our four decades of experience in flow-through synthesis of oligo manufacturing.
Read it now to explore five key areas in your oligonucleotid…
Article
How can you harness the potential of nucleic acid therapeutics?
At Cytiva, the new team is here to support you. We can help you throughout the
development of your manufacturing workflow for oligonucleotides
and the purification of mRNA drug subs…
Article
Top Process Development Trends for 2022 and a Look into 2023
FDA approved 37 drugs in 2022, within the normal range for the past decade or so. The European Medicines Agency (EMA) was even more successful—approving a record 55 therapies. More than half of thes…
Article
Future Downstream Process Development Solutions for Advanced Therapies
downstream
Click here to view more Industry Leader Q&As >>
Peter Guterstam, PhD, Product Manager of Next Generation Resins & Technologies at Cytiva, provides insight into solutions for ad…